The 2 responders treated by chemotherapy plus trastuzumab had an ERBB2 S310Y mutated tumor, affecting the extracellular domain of HER2, confirming the preclinical demonstration of sensitivity to trastuzumab [17]. Here, ERBB2 is linked to neoplasm.